Cyclin D1 as a therapeutic target of renal cell carcinoma- a combined transcriptomics, tissue microarray and molecular docking study from the Kingdom of Saudi Arabia. Issue 2 (September 2016)

• Record Type: Journal Article
• Authors: Karim, Sajjad; Al-Maghrabi, Jaudah; Farsi, Hasan; Al-Sayyad, Ahmad; Schulten, Hans-Juergen; Buhmeida, Abdelbaset; Mirza, Zeenat; Al-boogmi, Alaa; Ashgan, Fai; Shabaad, Manal; NourEldin, Hend; Al-Ghamdi, Khalid; Abuzenadah, Adel; Chaudhary, Adeel; Al-Qahtani, Mohammed
• Is Part Of: BMC cancer. Volume 16:Issue 2(2016)
• Page Start: 9
• Page End: 21
• Publication Date: 2016-09
• Subjects: Renal cell carcinoma -- Cyclin D1 -- Gene expression profiling -- Tissue microarray -- Molecular docking -- Therapeutic target -- Saudi Arabia; Cancer -- Periodicals; 616.994005
• DOI: 10.1186/s12885-016-2775-2
• Languages: English
• ISSNs: 1471-2407

Abstract

Abstract Background Renal cell carcinoma (RCC) is a seventh ranked malignancy with poor prognosis. RCC is lethal at metastatic stage as it does not respond to conventional systemic treatments, and there is an urgent need to find out promising novel biomarkers for effective treatment. The goal of this study was to evaluate the biomarkers that can be potential therapeutic target and predict effective inhibitors to treat the metastatic stage of RCC. Methods We conducted transcriptomic profiling to identify differentially expressed genes associated with RCC. Molecular pathway analysis was done to identify the canonical pathways and their role in RCC. Tissue microarrays (TMA) based immunohistochemical stains were used to validate the protein expression of cyclinD1 (CCND1) and were scored semi-quantitatively from 0 to 3+ on the basis of absence or presence of staining intensity in the tumor cell. Statistical analysis determined the association of CCND1 expression with RCC. Molecular docking analyses were performed to check the potential of two natural inhibitors, rutin and curcumin to bind CCND1. Results We detected 1490 significantly expressed genes (1034, upregulated and 456, downregulated) in RCC using cutoff fold change 2 andp value < 0.05. Hes-related family bHLH transcription factor with YRPW motif 1 (HEY1), neuropilin 2 (NRP2), lymphoid enhancer-binding factor 1 (LEF1), and histone cluster 1 H3h (HIST1H3H) were most upregulated while aldolase B, fructose-bisphosphate (ALDOB), solute carrier family 12 (SLC12A1), calbindin 1 (CALB1) were the most down regulated genes in our dataset. Functional analysis revealed Wnt/β-catenin signaling as the significantly activated canonical pathway (z score = 2.53) involving cyclin D1 (CCND1). CCND1 was overexpressed in transcriptomic studies (FC = 2.26, p value = 0.0047) and TMA results also showed the positive expression of CCND1 in 53 % (73/139) of RCC cases. The ligands – rutin and curcumin bounded with CCND1 with good affinity. Conclusion CCND1 was one of the important upregulated gene identified in microarray and validated by TMA. Docking study showed that CCND1 may act as a potential therapeutic target and its inhibition could focus on the migratory, invasive, and metastatic potential of RCC. Further in vivo and in vitro molecular studies are needed to investigate the therapeutic target potential of CCND1 for RCC treatment.